Juvenile toxicology studies are critical in pediatric drug development. These studies help identify age-specific toxicities and safeguard the health of our youngest patients. Explore more: https://hubs.li/Q02MJZTf0 #PediatricMedicine #DrugDevelopment #Toxicology #Pharmaceuticals #Healthcare #JuvenileTox
WuXi AppTec, Laboratory Testing Division
Pharmaceutical Manufacturing
Plainsboro, NJ 5,099 followers
Your success is our success.
About us
As a global company with operations across Asia, Europe, and North America, WuXi AppTec provides a broad portfolio of R&D and manufacturing services that enable the global pharmaceutical and life sciences industry to advance discoveries and deliver groundbreaking treatments to patients. Through its unique business models, WuXi AppTec’s integrated, end-to-end services include chemistry drug CRDMO (Contract Research, Development and Manufacturing Organization), biology discovery, preclinical testing and clinical research services, advanced therapies CTDMO (Contract Testing, Development and Manufacturing Organization), helping customers improve the productivity of advancing healthcare products through cost-effective and efficient solutions. WuXi AppTec received an AA ESG rating from MSCI for the third consecutive year in 2023 and its open-access platform is enabling more than 6,000 customers from over 30 countries to improve the health of those in need – and to realize the vision that "every drug can be made and every disease can be treated.“ Our state-of-the-art Laboratory Testing Division in New Jersey provides leading bioanalytical & drug metabolism contract research services to a global customer base of pharmaceutical, biotech & agrochemical firms. Our bioanalytical services support a wide range of compounds-small & large molecules, new modalities including oligonucleotides, ADC, bispecific antibodies & more-from discovery to preclinical IND-enabling & regulated clinical studies. Capabilities include LC-MS/MS & immunochemistry platforms for GLP & non-GLP & customized Central Laboratory services to facilitate global clinical studies. Our comprehensive drug metabolism services are tailored to support the entire drug development cycle, from early discovery through IND-enabling to late-stage clinical development. Capabilities include in vivo pharmacokinetics, in vitro ADME, in vitro & in vivo biotransformation, & non-clinical radiolabel ADME (mass balance & QWBA).
- Website
-
https://labtesting.wuxiapptec.com/
External link for WuXi AppTec, Laboratory Testing Division
- Industry
- Pharmaceutical Manufacturing
- Company size
- 201-500 employees
- Headquarters
- Plainsboro, NJ
- Type
- Public Company
- Founded
- 1987
- Specialties
- ADME, DMPK, bioanalysis, drug metabolism, animal health, and agrochemical
Locations
-
Primary
107 Morgan Lane
Plainsboro, NJ 08536, US
-
6 Cedar Brook Dr
Cranbury, NJ 08512, US
Employees at WuXi AppTec, Laboratory Testing Division
-
Virginia Pate Whitaker
Senior Manager - Laboratory Operations at WuXi AppTec
-
Kristin Peterson
Director, Business Development, Western US Region and APAC at WuXi AppTec
-
Keith Ciccaglione
Scientist II at WuXi AppTec, Laboratory Testing Division, New Jersey site
-
TJ Sigler
Executive Director, Head of International Sales & Marketing | Laboratory Testing Division at WuXi AppTec
Updates
-
Effective communication during non-clinical testing ensures that protocols are executed flawlessly, data is recorded accurately, and issues are addressed promptly. This is essential for maintaining the testing process's integrity and ensuring timelines are met. Leaders who excel in communication can better coordinate diverse teams, manage resources efficiently, and maintain the rigorous standards required during this crucial stage. How important is communication during non-clinical testing? https://hubs.ly/Q02D4xLQ0 #DrugDevelopment #Non-clinicalTesting #Pharmaceuticals #Communication
Why Communication is Essential to Non-clinical Testing
https://labtesting.wuxiapptec.com
-
Cancer continues to be a global challenge, but innovations like Antibody-Drug Conjugates (ADCs) are revolutionizing treatment. ADCs combine the precision of monoclonal antibodies with the potency of cytotoxic drugs, offering targeted and effective therapies with reduced side effects. In our latest blog, we dive deep into the mechanisms, challenges, and regulatory aspects of ADC bioanalysis. Discover how we're paving the way for more personalized and less invasive cancer treatments. #CancerResearch #ADC #Bioanalysis #PharmaInnovation #PrecisionMedicine Read more: https://hubs.li/Q02MCB0m0
Clinical Bioanalysis Strategy for Antibody Drug Conjugates (ADCs)
https://labtesting.wuxiapptec.com
-
Embarking on an IND submission demands a nuanced understanding of key components. Immerse yourself in our comprehensive guide to comprehend the intricacies of IND study strategy planning. From DMPK studies unraveling drug behavior to toxicology assessments ensuring safety, and bioanalytical studies measuring drug concentrations, we decipher the complexity of IND study strategy planning: https://hubs.li/Q02D4Nkg0 #IND #ClinicalTrials #DrugDevelopment #StudyDesign
Key Components of IND Study Strategy Planning
https://labtesting.wuxiapptec.com
-
We’re proud to be joining toxicology experts from around the world at the #EUROTOX 2024 Congress from September 8-11, 2024. We hope to see you at Booth 22! 📍Plan to attend our session: Title: Mastering Drug Readiness: Navigating Preclinical Challenges with Expert Testing Partners Presenter: Susan McPherson, Executive Director of Toxicology at WuXi AppTec’s Laboratory Testing Division Date: Monday, September 9 Time: 12:00-1:00 Our experts are also presenting a pair of posters at the congress: Method Development Optimization for Intravesical Instillation in the Rat Author: Susan McPherson Poster #: P20-18 Validating Multi-Ion Channel Inhibition Assays Following Best Practice Considerations Author: Yuewen Cao Poster #: P01-06 Schedule time to speak with one of our subject matter experts: https://lnkd.in/giyS4CCh
-
-
IND approval is a critical milestone in drug development. As sponsors navigate potential drug developer partners, there are three critical components to consider. In our latest blog, we explore how you can find the right laboratory testing partner. https://hubs.li/Q02D4F4T0 #IND #ClinicalTrials #INDApplication #LabratoryTestingPartner
Finding the Best Lab Partner for your IND Submission
https://labtesting.wuxiapptec.com
-
Dive into our latest blog to discover the biological significance and bioanalytical strategies of biomarkers with a focus on complement detection. From the Nobel-winning discovery of the complement system to its crucial role in preclinical drug development, this article covers it all. #Biomarkers #ComplementSystem #DrugDevelopment #Bioanalysis #PharmaInnovation #WuXiAppTec • Explore how different complement pathways are activated and their impact on drug safety and efficacy. • Learn about the importance of complement detection in evaluating pharmacological effects and predicting toxic side effects. • Stay ahead with insights on the latest therapies and technologies in complement detection. Read more: https://hubs.li/Q02LC8w-0
Biological Significance and Bioanalytical Strategies of Biomarkers – Complement Detection
https://labtesting.wuxiapptec.com
-
Small molecule drugs are making a comeback in oncology, but their development is rigorously regulated to ensure safety and efficacy. From preclinical testing to market approval, understanding these regulatory pathways is essential for innovators in small molecule therapeutics. Learn more about these critical processes. https://hubs.li/Q02H_0nh0 #Oncology #CancerResearch #DrugDevelopment #RegulatoryStandards
Preparing for the golden age of small molecule oncology drugs
https://www.drugdiscoverytrends.com
-
Antibody-drug conjugates (ADCs) offer an exciting look into the future of cancer therapy. This article showcases the role of LC-MS/MS in enhancing the development and analysis of these potent cancer-fighting drugs. Understand why LC-MS/MS is the go-to technique for accurate, efficient, and cost-effective drug analysis. #ADCDrugs #LCMS #BioassayOptimization #DrugDevelopment #CancerResearch https://hubs.li/Q02JG6dy0
-
-
Precision medicine is transforming healthcare, and biomarkers are at the heart of this revolution. These measurable indicators enhance our understanding of disease mechanisms and how we respond to treatment. The 'Fit-for-Purpose' strategy offers a flexible, tailored approach to biomarker validation, ensuring that drug development is efficient and aligned with specific therapeutic goals. Discover how this strategy paves the way for personalized treatments to individual patient needs, promising a future where healthcare is more effective and targeted than ever. #precisionmedicine #drugdevelopment #biomarkers https://hubs.li/Q02LD3Md0
Tailored Treatment: Biomarkers and the Path to Precision Medicine Based on a ‘Fit-for Purpose’ Strategy
americanpharmaceuticalreview.com